Lymphoma/Myeloma Dept, MD Anderson Cancer Center, United States
Dr. Michael Wang, MD, is a distinguished physician and researcher specializing in lymphoma, myeloma, and stem cell transplantation. He is currently a Professor at The University of Texas MD Anderson Cancer Center, where he has been serving since 2013. Dr. Wang has made significant contributions to the field, particularly in the understanding and treatment of lymphoma and myeloma. He holds multiple state licenses, including Arizona, Alabama, and Georgia, and has a wealth of experience in oncology and hematology. Dr. Wang’s work is highly recognized, earning him several prestigious awards, such as the “Top Doctor” award in 2020. He also directs the Mantle Cell Lymphoma Program of Excellence at MD Anderson, and serves as a co-principal investigator on the B-cell Lymphoma Moonshot Project. His professional efforts are complemented by his active participation in numerous research initiatives aimed at improving patient outcomes.
Profile
Scopus
EducationΒ
Dr. Wang obtained his Medical Doctorate (MD) from Shandong Medical University, China, in 1985. He furthered his education with a Master’s in Physiology from Beijing Medical University in 1988. He later completed several fellowships and specialized training in the United States. Dr. Wang pursued a medical oncology/hematology fellowship at The University of Texas MD Anderson Cancer Center from 1999 to 2002. Prior to this, he worked as an attending physician at Kelsey-Seybold Clinic, Houston, from 1998 to 1999. His early career also saw him at Yale-Norwalk Hospital, where he completed his residency in medicine (1995β1997) and served as Chief Medical Resident (1997β1998). Additionally, Dr. Wang gained valuable experience through visiting fellowships at the National Institutes of Health (NIH), where he conducted research in molecular biology and cell biology. His academic foundation has laid the groundwork for his transformative contributions to lymphoma and hematology.
ExperienceΒ
Dr. Wang’s clinical and research career has spanned multiple prestigious institutions. Since joining The University of Texas MD Anderson Cancer Center in 2013, he has served as a Professor in the departments of Lymphoma/Myeloma and Stem Cell Transplantation. He currently holds the Puddin Clarke Professorship in Multiple Myeloma Research. Additionally, he co-leads the B-cell Lymphoma Moonshot Project and directs the Mantle Cell Lymphoma Program of Excellence. His academic journey began with notable fellowships and residencies, which included time spent at Yale-Norwalk Hospital and The University of Michigan Hospitals. Over the years, Dr. Wang has developed expertise in lymphoma, hematology, and stem cell transplantation, which he applies in his clinical practice. His leadership in pioneering research and clinical trials has positioned him as a thought leader in lymphoma and myeloma treatment, driving innovations in patient care and therapeutic strategies.
Awards and HonorsΒ
Dr. Michael Wang’s exemplary career has earned him numerous prestigious awards and honors. In 2020, he was named a “Top Doctor,” recognizing his outstanding clinical expertise. In 2017, he received the Outstanding Service Award from the Chinese American Hematologist Oncologist Network. Dr. Wang was also recognized by the U.S. Congress in 2016 with a Certificate of Special Congressional Recognition for his invaluable contributions to the community. Among his academic distinctions, Dr. Wang received the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research in 2016. He also received the Waun Ki Hong Award for Excellence in Team Science from MD Anderson Cancer Center in 2015. His consistent recognition reflects his leadership and significant impact on clinical research in hematology and oncology. These accolades underline his contributions to the medical field and his commitment to advancing cancer treatment.
Research Focus
Dr. Michael Wang’s research focuses primarily on the treatment and understanding of lymphoma, myeloma, and stem cell transplantation. His work addresses therapeutic strategies in B-cell lymphomas and the molecular mechanisms underlying mantle cell lymphoma. As the director of the Mantle Cell Lymphoma Program of Excellence at MD Anderson, he is at the forefront of exploring novel therapies to improve patient outcomes. His research also delves into resistance mechanisms in mantle cell lymphoma, particularly focusing on the HSP90-MYC-CDK9 network. Additionally, Dr. Wang has contributed significantly to the development of immunotherapies, including CAR-T cell therapies. His work in clinical trials explores the safety and efficacy of combining targeted therapies with traditional treatments. Through his role in the B-cell Lymphoma Moonshot Project, Dr. Wang is driving efforts to accelerate breakthroughs in lymphoma treatment. His research has the potential to transform patient care by identifying personalized, more effective therapies.
Publications
- TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present π§¬π
- SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma? π§ͺπ¬
- The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma ππ‘
- Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001 π§βπ¬π
- CD5 deletion enhances the antitumor activity of adoptive T cell therapies ππ¦
- Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma ππ§¬
- Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma π«π―